This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
Tucatinib is the third approved HER2 kinase inhibitor (after lapatinib and neratinib), but differentiates itself due to its selectivity against the…
molecule
2 years ago ●
1 min read
S6821 is one of two potent and selective TAS2R8 GPCR antagonists disclosed by Firmenich, a fragrance and flavor company. These compounds…
molecule
2 years ago ●
1 min read
April 2020’s molecule, the Mirati KRAS G12C inhibitor MRTX849, has been a hotly followed compound in development as it is the…
molecule
2 years ago ●
1 min read
BAY1161909 is one of two clinical candidates disclosed in a single paper from Bayer. The compounds have an interesting anti-cancer mechanism…
molecule
2 years ago ●
1 min read
ORN0829 is a dual inhibitor of orexins 1 and 2, designed to have a relatively short half life in humans for…
molecule
2 years ago ●
1 min read
BMS-986251 is an inverse agonist of RORgt, a hot target in inflammation for a significant period. Unfortunately it looks like development…
molecule
2 years ago ●
1 min read
Load More
